These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12520638)

  • 1. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
    Lin E; Morris JS; Ayers GD
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):31-7. PubMed ID: 12520638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
    Lin EH; Curley SA; Crane CC; Feig B; Skibber J; Delcos M; Vadhan SR; Morris J; Ayers GD; Ross A; Brown T; Rodriguez-Bigas MA; Janjan N
    Am J Clin Oncol; 2006 Jun; 29(3):232-9. PubMed ID: 16755175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
    Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G
    Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
    Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
    Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL
    Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
    Masferrer JL; Leahy KM; Koki AT; Zweifel BS; Settle SL; Woerner BM; Edwards DA; Flickinger AG; Moore RJ; Seibert K
    Cancer Res; 2000 Mar; 60(5):1306-11. PubMed ID: 10728691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
    Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.
    Williams CS; Watson AJ; Sheng H; Helou R; Shao J; DuBois RN
    Cancer Res; 2000 Nov; 60(21):6045-51. PubMed ID: 11085526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
    Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
    Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
    Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
    Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
    Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
    Trifan OC; Durham WF; Salazar VS; Horton J; Levine BD; Zweifel BS; Davis TW; Masferrer JL
    Cancer Res; 2002 Oct; 62(20):5778-84. PubMed ID: 12384538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.